Why the study?
Contemporary evidence on circulating cardiac biomarkers needed to be summarized to identify a promising biomarker model for personalized point-of-care heart failure management.
This narrative review provides a comprehensive overview of circulating cardiac biomarkers in heart failure, highlighting their potential for personalized point-of-care management and future multi-omics directions.
Answers are grounded in this paper and cite their sources.
May inform HF biomarker discussions in practice; leaves open prospective validation of guided strategies.
The aim of this narrative review is to summarize contemporary evidence on the use of circulating cardiac biomarkers of heart failure (HF) and to identify a promising biomarker model for clinical use in personalized point-of-care HF management. We discuss the reported biomarkers of HF classified into clusters, including myocardial stretch and biomechanical stress; cardiac myocyte injury; systemic, adipocyte tissue, and microvascular inflammation; cardiac fibrosis and matrix remodeling; neurohumoral activation and oxidative stress; impaired endothelial function and integrity; and renal and skeletal muscle dysfunction. We focus on the benefits and drawbacks of biomarker-guided assistance in daily clinical management of patients with HF. In addition, we provide clear information on the role of alternative biomarkers and future directions with the aim of improving the predictive ability and reproducibility of multiple biomarker models and advancing genomic, transcriptomic, proteomic, and metabolomic evaluations.
No takes yet. Share an insight, caveat, or question.
Berezin et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: